MAP1B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL29427473	0.50	1/20
SCHEMBL18694532	0.49	1/20
SCHEMBL20127887	0.49	1/20
SCHEMBL20127890	0.49	1/20
SCHEMBL20896874	0.48	1/20
SCHEMBL22631674	0.48	1/20
SCHEMBL19134196	0.48	1/20
Hydrochloric Acid (SCHEMBL20896828)	0.48	1/20
SCHEMBL23153092	0.47	1/20
SCHEMBL22368144	0.47	1/20
SCHEMBL23153093	0.47	1/20
SCHEMBL23153094	0.47	1/20
SCHEMBL18166078	0.46	1/20
SCHEMBL16801243	0.46	1/20
SCHEMBL16801317	0.46	1/20
SCHEMBL22368122	0.46	1/20
SCHEMBL22368146	0.46	1/20
SCHEMBL29875637	0.46	1/20
SCHEMBL21937147	0.45	1/20
SCHEMBL21937148	0.45	1/20

Clinical trials — most relevant to MAP1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
Memantine Therapy in Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia	PHASE2	COMPLETED
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age	PHASE2	ACTIVE_NOT_RECRUITING
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations	PHASE2	COMPLETED
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)	PHASE1/PHASE2	NOT_YET_RECRUITING
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia	PHASE1	UNKNOWN
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.	PHASE1	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults	PHASE1	COMPLETED
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Exploratory Evaluation of [11C]MPC6827	EARLY_PHASE1	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Evaluation of a Novel PET Radioligand to Image OGA	nan	COMPLETED
Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients	nan	COMPLETED
Neurofilament Surveillance Project (NSP)	nan	ACTIVE_NOT_RECRUITING
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
The Imperial Comprehensive Cognitive Assessment in Cerebrovascular Disease (IC3)	nan	RECRUITING
Identification of New FTLD Genes	nan	UNKNOWN
Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis	nan	COMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease	nan	RECRUITING
Molecular Profile of the Evolution of Inclusion Body Myositis	nan	COMPLETED
Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices	nan	ACTIVE_NOT_RECRUITING
Effect of Low Dose of Colchicine on Platelet Reactivity	nan	COMPLETED
Myotubular and Centronuclear Myopathy Patient Registry	nan	RECRUITING
Explore Biomarkers of Motor Neuron Disease/Frontal Dementia Spectrum Disease in China	nan	ENROLLING_BY_INVITATION
Study of Degenerescence CSF Hallmarks in Older Bipolar Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAP1B binder may also engage these)

Protein	Name	Similarity
P15205	—	1.000	P15205 →
P14873	—	1.000	P14873 →
P14400	—	0.989	P14400 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.989	landscape →
Q498F0	—	0.987	Q498F0 →
E1BTG2	—	0.986	E1BTG2 →
Q6PDG5	—	0.986	Q6PDG5 →
Q9XSC3	—	0.985	Q9XSC3 →
Q6NVE8	—	0.984	Q6NVE8 →
Q3UQU0	—	0.984	Q3UQU0 →
Q9ULJ8	—	0.984	Q9ULJ8 →
G3UZ78	—	0.983	G3UZ78 →
Q5F3A1	—	0.982	Q5F3A1 →
Q9R037	—	0.982	Q9R037 →
Q9QYR6	—	0.982	Q9QYR6 →
Q9SU25	—	0.982	Q9SU25 →
Q69ZZ6	—	0.982	Q69ZZ6 →
P34926	—	0.981	P34926 →
Q9FLU1	—	0.981	Q9FLU1 →
Q2IA00	—	0.981	Q2IA00 →
Q5E9D0	—	0.981	Q5E9D0 →
Q5F3A4	—	0.981	Q5F3A4 →
Q69ZX6	—	0.981	Q69ZX6 →
Q8C5W4	—	0.980	Q8C5W4 →
Q5VWG9	—	0.980	Q5VWG9 →
Q96D71	—	0.980	Q96D71 →
BRD9	Bromodomain-containing protein 9	0.980	landscape →
P78559	—	0.980	P78559 →
Q0VAK6	—	0.980	Q0VAK6 →
Q6DD45	—	0.980	Q6DD45 →